ClinicalTrials.Veeva

Menu

A Study of Bimagrumab in Participants With HFpEF (ACTIVATE-HFpEF)

Lilly logo

Lilly

Status and phase

Not yet enrolling
Phase 2

Conditions

Heart Failure, Diastolic
Heart Failure, Normal Ejection Fraction
Heart Failure, Preserved Ejection Fraction
Diastolic Heart Failure

Treatments

Drug: Placebo
Drug: Bimagrumab

Study type

Interventional

Funder types

Industry

Identifiers

NCT07920887
27879
2026-527983-34-00 (EU Trial (CTIS) Number)
J4Z-MC-GIDK (Other Identifier)

Details and patient eligibility

About

This study will look at how bimagrumab affects adults who have a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart pumps normally but does not fill with blood as well as it should. Participation in the study will last about 76 weeks.

Enrollment

540 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Have New York Heart Association Class II to III heart failure

  • Have left ventricular ejection fraction (LVEF) ≥ 50%

  • KCCQ-CSS ≤ 80

  • 6MWD must be all of the following:

    • ≥100 and ≤ 450 meters (m) based on average of 2 tests conducted at screening visit, AND
    • ≥ 100 and ≤ 450 m on 1 test at randomization visit, AND
    • < 20% change from average qualifying 6MWD obtained at screening
  • Have documented evidence of at least one of the following:

    • Heart failure event
    • Elevated NT-proBNP (N-terminal pro B-type natriuretic peptide)
    • Left atrium enlargement
    • Elevated filling pressure
  • Stable dose of heart failure medications

  • Body mass index (BMI) ≥ 23 kilograms per meter squared (kg/m²)

Exclusion criteria

  • Heart failure hospitalization < 4 weeks before screening
  • Myocardial infarction, coronary artery bypass graft surgery, or other major cardiovascular surgery/intervention, stroke or transient ischemic attack in past 12 weeks prior to screening, or unstable angina pectoris in past 4 weeks prior to screening or during screening
  • Type 1 diabetes
  • Hemoglobin A1c (HbA1c) ≥ 9.5%

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

540 participants in 4 patient groups, including a placebo group

Bimagrumab Dose 1
Experimental group
Description:
Participants will receive bimagrumab subcutaneously (SC)
Treatment:
Drug: Bimagrumab
Bimagrumab Dose 2
Experimental group
Description:
Participants will receive bimagrumab SC
Treatment:
Drug: Bimagrumab
Placebo 1
Placebo Comparator group
Description:
Participants will receive placebo SC
Treatment:
Drug: Placebo
Placebo 2
Placebo Comparator group
Description:
Participants will receive placebo SC
Treatment:
Drug: Placebo

Trial contacts and locations

9

Loading...

Central trial contact

Physicians interested in becoming principal investigators please contact; Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems